Skip to main content
SpringerLink
Log in

Risk-Reducing Surgery and Treatment of Menopausal Symptoms in BRCA Mutation Carriers (and Other Risk Women)

  • Chapter
  • First Online:
Pre-Menopause, Menopause and Beyond

Part of the book series: ISGE Series ((ISGE))

  • 1238 Accesses

Abstract

Women with a life expectancy ≥10 years and no diagnosis/history of breast cancer who are considered to be at increased risk for breast cancer should receive counseling to decrease breast cancer risk, considering lifestyle factors, therapy with risk reduction agents, and risk reduction surgery (in BRCA1/2 mutation carriers).Bilateral risk-reducing mastectomy decreases the risk of developing breast cancer by at least 90%; it should be proposed to carefully selected women at high risk for breast cancer considering BRCA1/2 or other genetic mutations and previous history of LCIS. In current practice, atypical hyperplasia is not an indication for prophylactic mastectomy.Bilateral risk-reducing salpingo-oophorectomy decreases the risk of developing ovarian and fallopian cancer by 85–95% and breast cancer by 50% in BRCA1/2 mutation carriers when performed in premenopausal age. Peritoneal washing should be performed at surgery, and pathologic assessment should include fine sectioning of the ovaries and fallopian tubes. The additional benefit of concurrent hysterectomy is not clear at the time. In women with no personal history of breast cancer, short-term HRT use does not negate the protective effect of RRSO on subsequent breast cancer risk, and it should be offered until the time of expected natural menopause.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Antoniou A, Pharoah P, Narod S, Risch HA et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. NCCN Guidelines 1 (16 Dec 2016) Breast cancer risk reduction

    Google Scholar 

  3. Gail MH, Costantino JP (2001) Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 93(5):334–335

    Article  CAS  PubMed  Google Scholar 

  4. Hartmann LC et al (2015) Atypical hyperplasia of the breast, risk assessment and management options. N Engl J Med 372:78–89

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hartmann LC, Radisky DC, Frost MH et al (2014) Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) 7:211–217

    Article  CAS  Google Scholar 

  6. Hartmann LC et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84

    Article  CAS  PubMed  Google Scholar 

  7. Giuliano AE, Boolbol S, Degnim A et al (2007) Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol 14(9):2425–2427

    Article  PubMed  Google Scholar 

  8. Giuliano AE, Boolbol S, Degnim A, Henry K, Marilyn Leitch A, Morrow M (2007) Annals of. Surg Oncol 14(9):2425–2427. doi:10.1245/s10434-007-9447-z

    Article  Google Scholar 

  9. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kauff ND, Domchek SM, Friebel ME et al (2008) Risk-reducing salpingooophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26:1331–1337

    Article  PubMed  PubMed Central  Google Scholar 

  11. Eisen A, Lubinski J, Klijn J et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496

    Article  PubMed  Google Scholar 

  12. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622

    Article  PubMed  Google Scholar 

  13. RIGENIO Guidelines (2007) Regione Piemonte

    Google Scholar 

  14. Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185–192

    Article  CAS  PubMed  Google Scholar 

  15. Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y et al (2004) BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92:521–524

    Article  CAS  PubMed  Google Scholar 

  16. Finch A, Shaw P, Rosen B et al (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100:58–64

    Article  CAS  PubMed  Google Scholar 

  17. Colgan TJ, Boerner SL, Murphy J, Cole DE, Narod S, Rosen B (2002) Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 85(3):397–403

    Article  PubMed  Google Scholar 

  18. Kwon JS, Tinker A, Pansegrau G et al (2013) Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA. Obstet Gynecol 121:14–24

    Article  PubMed  Google Scholar 

  19. Cibula D, Widschwendter M, Májek O, Dusek L (2011) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 17(1):55–67

    Article  CAS  PubMed  Google Scholar 

  20. Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C et al (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121(1):163–168

    Article  CAS  PubMed  Google Scholar 

  21. Cohen JV, Chiel L, Boghossian L, Jones M, Domchek SM et al (2012) Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Familial Cancer 11(1):69–75

    Article  CAS  PubMed  Google Scholar 

  22. Shukla PC, Singh KK, Quan A et al (2011) BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2:593

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rebbeck TR, Friebel T, Wagner T et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810

    Article  CAS  PubMed  Google Scholar 

  24. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19):1361–1367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB (2014) Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 21(7):763–768

    Article  PubMed  Google Scholar 

  26. International Menopause Society (IMS) (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16:316–337

    Article  Google Scholar 

  27. Von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group (2005) Menopausal hormone replacement therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 97:533–535

    Article  Google Scholar 

  28. Holmberg L, Anderson H (2004) For the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455

    Article  CAS  PubMed  Google Scholar 

  29. Holmberg L, Iversen OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482

    Article  CAS  PubMed  Google Scholar 

  30. Fahlén M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49(1):52–59

    Article  PubMed  Google Scholar 

  31. Kenemans P, Bundred NJ, Foidart JM et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial. Lancet Oncol 10:135–146

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Turin, “Umberto I Hospital”, Turin, Italy

    Piero Sismondi, Marta D’Alonzo, Paola Modaffari, Viola Liberale, Valentina Elisabetta Bounous, Andrea Villasco & Nicoletta Biglia

Authors
  1. Piero Sismondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta D’Alonzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Modaffari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Viola Liberale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valentina Elisabetta Bounous
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Villasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicoletta Biglia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piero Sismondi .

Editor information

Editors and Affiliations

  1. Professor emeritus for Gynaecological Endocrinology and Reproductive Medicine, University of Bern, Bern, Switzerland

    Martin Birkhaeuser

  2. International Society of Gynecological Endocrinology, Pisa, Italy

    Andrea R. Genazzani

Rights and permissions

Reprints and permissions

Copyright information

© 2018 International Society of Gynecological Endocrinology

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sismondi, P. et al. (2018). Risk-Reducing Surgery and Treatment of Menopausal Symptoms in BRCA Mutation Carriers (and Other Risk Women). In: Birkhaeuser, M., Genazzani, A. (eds) Pre-Menopause, Menopause and Beyond. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-63540-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63540-8_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63539-2

  • Online ISBN: 978-3-319-63540-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation